WallStSmart

Cosmos Health Inc. (COSM)vsMcKesson Corporation (MCK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

McKesson Corporation generates 580483% more annual revenue ($403.43B vs $69.49M). MCK leads profitability with a 1.2% profit margin vs -30.4%. MCK earns a higher WallStSmart Score of 55/100 (C).

COSM

Hold

41

out of 100

Grade: D

Growth: 6.7Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: -2.45

MCK

Buy

55

out of 100

Grade: C

Growth: 8.0Profit: 4.5Value: 4.7Quality: 7.0
Piotroski: 5/9Altman Z: 5.40
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COSM.

MCKSignificantly Overvalued (-65.1%)

Margin of Safety

-65.1%

Fair Value

$577.34

Current Price

$763.51

$186.17 premium

UndervaluedFair: $577.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COSM2 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
30.7%10/10

Revenue surging 30.7% year-over-year

MCK5 strengths · Avg: 9.0/10
Debt/EquityHealth
-3.9710/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
5.4010/10

Safe zone — low bankruptcy risk

Market CapQuality
$89.39B9/10

Large-cap with strong market position

EPS GrowthGrowth
37.2%8/10

Earnings expanding 37.2% YoY

Free Cash FlowQuality
$3.31B8/10

Generating 3.3B in free cash flow

Areas to Watch

COSM4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-106.6%2/10

ROE of -106.6% — below average capital efficiency

Free Cash FlowQuality
$-1.08M2/10

Negative free cash flow — burning cash

MCK3 concerns · Avg: 3.0/10
Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
1.2%3/10

1.2% margin — thin

Operating MarginProfitability
2.2%3/10

Operating margin of 2.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : COSM

The strongest argument for COSM centers on Price/Book, Revenue Growth. Revenue growth of 30.7% demonstrates continued momentum.

Bull Case : MCK

The strongest argument for MCK centers on Debt/Equity, Altman Z-Score, Market Cap. PEG of 1.49 suggests the stock is reasonably priced for its growth.

Bear Case : COSM

The primary concerns for COSM are EPS Growth, Market Cap, Return on Equity.

Bear Case : MCK

The primary concerns for MCK are Return on Equity, Profit Margin, Operating Margin. Thin 1.2% margins leave little buffer for downturns.

Key Dynamics to Monitor

COSM profiles as a hypergrowth stock while MCK is a value play — different risk/reward profiles.

COSM carries more volatility with a beta of 4.12 — expect wider price swings.

COSM is growing revenue faster at 30.7% — sustainability is the question.

MCK generates stronger free cash flow (3.3B), providing more financial flexibility.

Bottom Line

MCK scores higher overall (55/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cosmos Health Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cosmos Holdings Inc. is a vertically integrated pharmaceutical company. The company is headquartered in Chicago, Illinois.

McKesson Corporation

HEALTHCARE · MEDICAL DISTRIBUTION · USA

McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.

Visit Website →

Want to dig deeper into these stocks?